Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Replimune stock rally 46% on leaked RP1 and RP2 clinical trial data
Replimune on LinkedIn: Today, we present updated data on RP2 in uveal ...
Replimune launches Phase I trial of RP2 in cancer patients
Novel Replimune RP2 Treatment for Metastatic Uveal Melanoma - A Cure In ...
Replimune Highlights RP1, RP2 Progress Ahead of JPM Conference ...
Replimune Scraps RP2 and RP3 Clinical Programs After Phase 2 Miss ...
RP2-202 - Replimune | A Cure In Sight™
Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of ...
Replimune Accepts FDA BLA Resubmission for RP1; PDUFA Apr 10, 2026 ...
Replimune Aktie: RP2-Daten beim ASCO Ende Mai entscheidend
Replimune resubmits melanoma drug for FDA approval
Culture and Careers | Replimune
Transforming Cancer Treatment | Replimune
Replimune Announces Positive Initial Data from the Anti-PD1 Failed ...
Pipeline - Replimune
Replimune (REPL): Scientific Deep Dive for RP1, RP2, and Pipeline Products
Replimune Group, Inc. - AnnualReports.com
JAG Black RP2 Pod Kit — Yateley Angling Centre
Replimune Shares Surge After Early Data From Pretreated Melanoma Patients
Replimune on LinkedIn: #asco24
Broth Agency | Replimune Case Study
Replimune präsentiert positive Daten aus den klinischen Programmen Rp1 ...
Compra acciones de Replimune | Precio de $REPL | Lightyear
Wedbush Upgrades Replimune Group (REPL), Raises Price Target Sig
Replimune 2022 Investor Day: RP1 in Skin Cancer
6 Reasons Why Replimune Offers Huge Growth Potential!
Replimune Shares Surge on Regulatory Breakthrough
( A ) Expression of RP2 in lymphoblastoid cells from a control male ...
#asco23 | Replimune
Science | Replimune
Replimune Shares Signal Potential Rebound Following Key Developments
Medical Professionals | Replimune
Replimune on Behance
Replimune logo in transparent PNG and vectorized SVG formats
#breakingnews | Replimune | 46 comments
Replimune Aktie: Herausragende Marktentwicklung! - Börse Global
Replimune Stock: Multiple Shots On Goal But A High Risk Binary ...
Oncolytic Immunotherapy Pipeline | Replimune
Replimune (REPL) Stock Dips Amid FDA Meeting and Analyst Downgra
Replimune Soars Upon FDA Resubmission for Advanced Melanoma Drug - BioSpace
REPL - Replimune Group | Fundamentei
Replimune Group Presents Promising Clinical Data at J.P. Morgan Conference
Clinical Trials | Replimune
Replimune
Replimune kickstarts Phase III melanoma trial studying RP1 ...
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus ...
RP2 is enriched in distinct regions of the kidney. ( A ) RP2 staining ...
Replimune receives CRL on BLA for RP1 for advanced melanoma | pharmaphorum
RP2 localizes to primary cilium in epithelia. (A) Endogenous RP2 ...
RP2 forms a complex with polycystin 2. ( A ) Knockdown of RP2 by ...
🧬 Replimune Group (레플리뮨 그룹) 최신 소식 요약 : 네이버 블로그
Replimune Prepares for Type A Meeting With FDA on RP1 | Dermatology Times
Wedbush Upgrades Replimune Group (REPL)
#asco23 #oncologyresearch | Replimune
Replimune, Inc.: Replimune Receives Complete Response Letter from FDA ...
FDA Issues CRL to Replimune for Vusolimogene Oderparepvec With ...
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the ...
RP2 regulates polycystin 2 trafficking. ( A ) Ablation of RP2 results ...
Replimune: The Rise Of Oncolytic Virus Therapies In Cancer Treatment ...
Replimune与罗氏就开发RP2 / 3溶瘤病毒达成临床合作协议，用于治疗结直肠癌和肝细胞癌|免疫系统|临床|肿瘤|患者|癌症|-健康界
Replimune公司公布溶瘤病毒临床试验结果，双拳出击治疗晚期癌症|溶瘤病毒疗法|单纯疱疹病毒|免疫系统|癌症|肿瘤|-健康界
Replimune: A Misunderstood Contender In Oncolytics (NASDAQ:REPL ...
Learn more about $REPL’s recently announced collaboration with Roche ...
Replimune与罗氏就开发RP2/3溶瘤病毒达成临床合作协议，用于治疗结直肠癌和肝细胞癌_腾讯新闻
RP-2(Replimune Group)(RP-2(Replimune Group)) - 药物靶点：CSF-2R x CTLA4 x ...
Replimune與羅氏就開發RP2 / 3溶瘤病毒達成臨床合作協議 - 每日頭條
#replimune #rp1 #advancedmelanoma #oncolyticimmunotherapy #fdaapproval ...
Last week, we shared a comprehensive update on RP1. The full ...
Replimune: Strong Data In A Highly Differentiated Space (NASDAQ:REPL ...
Biotech Battle Royale: Replimune's High-Stakes Market Clash - Stocks Today
Replimune: Reducing Site and Patient Burden | 吃瓜爆料
GRAPHIC
mark (@pawpaw_mark) | Twitter
FDA Accepts Replimune's BLA for RP1 + Nivolumab in Melanoma | OncoDaily ...
Replimune: Reducing Site and Patient Burden | Veeva
Replimune与罗氏达成合作，开创新型肿瘤靶向溶瘤免疫疗法-咚咚肿瘤科
Replimune's RP1 Shows 44% Response in Acral Melanoma | REPL Stock News
溶瘤病毒领域群雄逐鹿，Replimune RP系列管线引领免疫治疗新篇章_摩熵医药(原药融云)
溶瘤病毒领域群雄逐鹿，Replimune RP系列管线引领免疫治疗新篇章_摩熵医药
Replimune's RP1 Achieves 33% Response Rate in Anti-PD1 Failed Melanoma ...
Replimune's (REPL) Turbulent Path: Assessing Long-Term Risks and ...
Replimune’s RP1 + Nivolumab Shows Promising Results in Melanoma Study
Dissecting Replimune’s RP1’s Surprising Setback
Replimune’s RP1 + Nivolumab Shows Promising Results in Melanoma Study ...
Replimune's RP1 Gains Breakthrough Status and Files FDA Application for ...
FDA Rejects Replimune’s RP1 Skin Cancer Therapy - Medicine to Market
